"For symptomatic treatment of rheumatoid arthritis, juvenile rheumatoid arthritis and osteoarthritis. May be used to treat mild to moderate pain and for the management of dysmenorrhea. May be used to reduce fever. Has been used with some success for treating ankylosing spondylitis, gout and psoriatic arthritis. May reduce pain, fever and inflammation of pericarditis. May be used IV with opiates to relieve moderate to severe pain. Ibuprofen lysine may be used IV to treat patent ductus arteriosus (PDA) in premature neonates. "@en . . "Nuprin"@en . . . . . . . "Mynosedin"@en . . . . . . . . . . "Trendar"@en . . . . . "Motrin"@en . "Suspren"@en . . "Brufen"@en . . . . . "Nobgen"@en . . "Rufen"@en . . "Ibu-attritin"@en . "Pediaprofen"@en . "Dolgit"@en . "Medipren"@en . "(+-)-P-Isobutylhydratropic acid"@en . "Food delays the time to reach peak plasma concentrations by 30-60 minutes and reduces peak plasma concentrations by 30-50%. Extent of absorption is unaffected."@en . "Humans and other mammals"@en . "(4-Isobutylphenyl)-alpha-methylacetic acid"@en . "The exact mechanism of action of ibuprofen is unknown. Ibuprofen is a non-selective inhibitor of cyclooxygenase, an enzyme invovled in prostaglandin synthesis via the arachidonic acid pathway. Its pharmacological effects are believed to be due to inhibition cylooxygenase-2 (COX-2) which decreases the synthesis of prostaglandins involved in mediating inflammation, pain, fever and swelling. Antipyretic effects may be due to action on the hypothalamus, resulting in an increased peripheral blood flow, vasodilation, and subsequent heat dissipation. Inhibition of COX-1 is thought to cause some of the side effects of ibuprofen including GI ulceration. Ibuprofen is administered as a racemic mixture. The R-enantiomer undergoes extensive interconversion to the S-enantiomer in vivo. The S-enantiomer is believed to be the more pharmacologically active enantiomer."@en . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . "Ibutid"@en . . . . . . . . . . "Advil"@en . . . . . . . . . . . . . . . . . . . "Para-Isobutylhydratropic Acid"@en . . . . "Dolo-dolgit"@en . . . . . . . . . . . . . " "@en . . . . . . . . . . . "Liptan"@en . . . . . . . . . . . . . . . . . . . . . . . . . . "Ibuprofen is rapidly metabolized and eliminated in the urine."@en . . . . . . . . . . . . . "Apsifen"@en . . . . . . . . . . "Ebufac"@en . . . . "Nurofen"@en . . . . . "Ibuprofen, a propionic acid derivative, is a prototypical nonsteroidal anti-inflammatory agent (NSAIA) with analgesic and antipyretic properties. "@en . . . . . . . . . . . . . . . . "Take with food to reduce gastric irritation."@en . . "~ 80% absorbed from GI tract

Time to reach peak plasma concentration = 47 minutes (suspension), 62 minutes (chewable tablets), 120 minutes (conventional tablets)

"@en . . . . . "Haltran"@en . "2-(4-Isobutylphenyl)propanoic acid"@en . "Ibuprofen"@en . . . "Brufort"@en . . . . . "(RS)-ibuprofen"@en . . . "15687-27-1"@en . "Nobfen"@en . "alpha-(P-Isobutylphenyl)propionic acid"@en . . . "(+-)-Ibuprofen"@en . . "approved"@en . . "Dolgirid"@en . "Amibufen"@en . "Ibuprocin"@en . . . . . . . . . . . . "Tabalon"@en . . "P-Isobutylhydratropic Acid"@en . . . "Butylenin"@en . . . . . . . "Anflagen"@en . . . . . . "Lamidon"@en . . . . . . . . . "Bluton"@en . "Dolgin"@en . . "90-99% to whole human plasma and site II of purified albumin, binding appears to be saturable and becomes non-linear at concentrations exceeding 20 mcg/ml."@en . "2-4 hours"@en . . "Ibuprofen"@en . . . . "Roidenin"@en . "Inabrin"@en . . "alpha-(4-Isobutylphenyl)propionic acid"@en . "Ibuprophen"@en . "# Zawada ET Jr: Renal consequences of nonsteroidal antiinflammatory drugs. Postgrad Med. 1982 May;71(5):223-30. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/7041104 # Townsend KP, Pratico D: Novel therapeutic opportunities for Alzheimer's disease: focus on nonsteroidal anti-inflammatory drugs. FASEB J. 2005 Oct;19(12):1592-601. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16195368 # Chen H, Jacobs E, Schwarzschild MA, McCullough ML, Calle EE, Thun MJ, Ascherio A: Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease. Ann Neurol. 2005 Dec;58(6):963-7. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16240369 # Geisslinger G, Dietzel K, Bezler H, Nuernberg B, Brune K: Therapeutically relevant differences in the pharmacokinetical and pharmaceutical behavior of ibuprofen lysinate as compared to ibuprofen acid. Int J Clin Pharmacol Ther Toxicol. 1989 Jul;27(7):324-8. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/2777420 # Bergner T, Przybilla B: Photosensitization caused by ibuprofen. J Am Acad Dermatol. 1992 Jan;26(1):114-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/1531054 # Dill J, Patel AR, Yang XL, Bachoo R, Powell CM, Li S: A molecular mechanism for ibuprofen-mediated RhoA inhibition in neurons. J Neurosci. 2010 Jan 20;30(3):963-72. doi: 10.1523/JNEUROSCI.5045-09.2010. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/20089905 "@en . "Ibumetin"@en . "Lebrufen"@en . "

Side effects: May cause peripheral edema and fluid retention. Use caution in patients with congestive heart failure or severe uncontrolled hypertension. May cause dyspepsia, heartburn, nausea, vomiting, anorexia, diarrhea, constipation, stomatitis, flatulence, bloating, epigastric pain, and abdominal pain. Peptic ulcer and GI bleeding have been reported. May also cause dizziness, headache and nervousness. Acute renal failure accompanied by acute tubular necrosis has been reported.

Most common symptoms of overdose are abdominal pain, nausea, vomiting, lethargy, vertigo, drowsiness (somnolence), dizziness and insomnia. Other symptoms of overdose include headache, loss of consciousness, tinnitus, CNS depression, convulsions and seizures. May rarely cause metabolic acidosis, abnormal hepatic function, hyperkalemia, renal failure, dyspnea, respiratory depression, coma, acute renal failure, and apnea (primarily in very young pediatric patients).

LD50=1255mg/kg(orally in mice)

"@en . "Buburone"@en . "Anco"@en . . . . "Epobron"@en . . . . . . . . . . . . . . . "Urem"@en . . "4-Isobutylhydratropic acid"@en . . . . . . . . "Femadon"@en . "Seclodin"@en . . . . . . . . . . . . . . . . . . . . . . "Inoven"@en . . "Avoid alcohol"@en . "http://en.wikipedia.org/wiki/Ibuprofen#Synthesis"@en . "(+-)-alpha-Methyl-4-(2-methylpropyl)benzeneacetic acid"@en . . . . . "(+-)-2-(P-Isobutylphenyl)propionic acid"@en . . . . "Adran"@en . . .